Alyssum Therapeutics Inc

Alyssum Therapeutics Inc, based in the US, focuses on developing innovative immunotherapy solutions that modulate B cells to treat complex diseases, primarily targeting cancers and autoimmune disorders. Alyssum Therapeutics Inc is engaged in the development of immunotherapy treatments that modulate B cells for complex diseases. Founded in 2018 in Cambridge, US, the company has completed 2 deals and raised a total of USD 2. 00 mn.

Their most recent funding was a Series A round, which occurred in January 2025 with an investment from FemHealth Ventures. The founder's details are not specified in the available information. Alyssum Therapeutics specializes in innovative immunotherapy solutions focused on modulating B cells to address complex diseases, particularly cancers and autoimmune disorders. The company's lead candidate, AT1965, is a small molecule currently in Phase 1 clinical trials for advanced solid malignancies.

AT1965 targets CMTR2 in cancer cells to stimulate a B cell immune response, showing promise in regressing hard-to-treat solid tumors and enhancing the efficacy of immune checkpoint inhibitors. The modulation of B cells aims to improve patient outcomes in various solid tumors, including breast cancer, melanoma, and cervical cancer. The company operates primarily in North America and Europe, with potential applications for their therapies extending to various oncology and autoimmune disease treatment markets. Alyssum Therapeutics generates revenue through partnerships and collaborations in the biopharmaceutical sector, focusing on the development of its flagship product, AT1965.

The company engages in B2B transactions with pharmaceutical companies and research institutions, facilitating licensing agreements and joint development initiatives. Revenue is derived from milestones achieved throughout the clinical trial phases, potential royalties on future product sales, and upfront payments from strategic partnerships. The pricing structure for their therapies is determined upon successful completion of clinical trials and subsequent commercialization agreements, aligning with industry standards for similar biopharmaceutical products. Specific pricing plans or revenue figures have not been disclosed.

Following their Series A funding round in January 2025, where Alyssum Therapeutics Inc raised USD 2. 00 mn from FemHealth Ventures, the company will utilize the funding to accelerate its research and development in immunotherapy studies. Future initiatives include the design and launch of new products aimed at addressing additional disease areas within oncology and autoimmune disorders. Additionally, the company plans to expand its operational reach into new markets in Europe by 2026 and the Asia-Pacific region by 2027.